Prescient Therapeutics Ltd has released a press release.
First Cohort Successfully Completed in Phase 1b/2 AML Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- December 2016 Appendix 4C - Quarterly
- First Patient Dosed on Phase 1b/2 AML Trial
- Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
- September 2016 Appendix 4C - Quarterly
- First patient at Moffitt dosed in Phase 1b/2 breast trial
Later from Prescient Therapeutics
- Three Additional US Patents Granted
- Successful Completion of Phase 1b Breast Cancer Trial
- March 2017 Appendix 4C - Quarterly
- FDA Grants Orphan Drug Designation for PTX-200 in AML
- Kansas University Joins PTXs AML Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics